As filed with the Securities and Exchange Commission on June 11, 2019
Registration No. 333-229660
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 2
to
Form S-4
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
MYND ANALYTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 8090 | 87-0419387 | ||
(State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | ||
incorporation or organization) | Classification Code Number) | Identification Number) |
26522 La Alameda, Suite 290
Mission Viejo, CA 92691
(949) 420-4400
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Patrick Herguth, Chief Executive Officer
MYnd Analytics, Inc.
26522 La Alameda, Suite 290
Mission Viejo, CA 92691
(949) 420-4400
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Jeffrey A. Baumel, Esq. Ilan Katz, Esq. Dentons US LLP 1221 Avenue of the Americas New York, New York 10020 (212) 768-6700 | Yutaka Niihara, M.D., M.P.H. Chairman and Chief Executive Officer Emmaus Life Sciences, Inc. 21250 Hawthorne Boulevard, Suite 800 Torrance, California 90503 (310) 214-0065 | Dale E. Short, Esq. General Counsel Emmaus Life Sciences, Inc. 21250 Hawthorne Boulevard, Suite 800 Torrance, California 90503 (310) 214-0065 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement and the satisfaction or waiver of all other conditions under the Merger Agreement described herein.
If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box:☐
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Transaction Act.
Large accelerated filer☐ | Accelerated filer☐ | |
Non-accelerated filer☐ | Smaller reporting company☒ | |
Emerging growth company☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.☐
If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction:
Exchange Act Rule 13e-4(i) (Cross-Border Issuer Tender Offer)☐
Exchange Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)☐
EXPLANATORY NOTE
This Amendment No. 2 to the MYnd Analytics, Inc. Registration Statement on Form S-4 (Registration No. 333-229660) originally filed with the Securities and Exchange Commission on February 13, 2019, as amended by Amendment No. 1 filed June 10, 2019, is being filed for the sole purpose of filing Exhibit 8.1 (and the related consent included therein as Exhibit 23.3) and updating the Exhibit Index accordingly. This Amendment No. 2 does not relate to the contents of the joint proxy statement/prospectus that forms a part of the Registration Statement and, accordingly, the joint proxy statement/prospectus has not been included herein.
PART II
INFORMATION NOT REQUIRED IN PROXY STATEMENT/PROSPECTUS
Item 20. Indemnification of Directors and Officers
The Registrant’s amended and restated certificate of incorporation contains provisions that eliminate, to the maximum extent permitted by the General Corporation Law of the State of Delaware, the personal liability of the Registrant’s directors and executive officers for monetary damages for breach of their fiduciary duties as directors or officers. The Registrant’s amended and restated certificate of incorporation and amended and restated bylaws provide that the Registrant must indemnify its directors and executive officers and may indemnify its employees and other agents to the fullest extent permitted by the General Corporation Law of the State of Delaware.
Sections 145 and 102(b)(7) of the General Corporation Law of the State of Delaware provide that a corporation may indemnify any person made a party to an action by reason of the fact that he or she was a director, executive officer, employee or agent of the corporation or is or was serving at the request of a corporation against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with such action if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of an action by or in right of the corporation, no indemnification may generally be made in respect of any claim as to which such person is adjudged to be liable to the corporation.
The Registrant has entered into indemnification agreements with its directors and executive officers, in addition to the indemnification provided for in its amended and restated certificate of incorporation and amended and restated bylaws, and intends to enter into indemnification agreements with any new directors and executive officers in the future.
The Registrant has purchased and intends to maintain insurance on behalf of any person who is or was a director or officer of the Registrant against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.
Item 21. Exhibits and Financial Statement Schedules
(a) Exhibit Index
A list of exhibits filed with this registration statement on Form S-4 is set forth on the Exhibit Index and is incorporated herein by reference.
(b) Financial Statements
The financial statements filed with this registration statement on Form S-4 are set forth on the Financial Statement Index and is incorporated herein by reference.
Item 22. Undertakings
(a) The undersigned registrant hereby undertakes as follows:
(1) That prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form.
(2) That every prospectus (i) that is filed pursuant to paragraph (a)(1) immediately preceding, or (ii) that purports to meet the requirements of Section 10(a)(3) of the Securities Act and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
II-1
(3) To respond to requests for information that is incorporated by reference into this joint proxy statement/prospectus/prospectus pursuant to Item 4, 10(b), 11, or 13 of Form S-4, within one business day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request.
(4) To supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective.
(b) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
II-2
EXHIBIT INDEX
II-3
II-4
21.1 | Subsidiaries of the Registrant | 10-K | 001-35527 | 21.1 | December 29, 2017 | MYnd | ||||||
23.1* | Consent of Marcum LLP, Independent Registered Public Accounting Firm | |||||||||||
23.2* | Consent of SingerLewak LLP, Independent Registered Public Accounting Firm | |||||||||||
23.3** | Consent of Dentons U.S. LLP (included in Exhibit 8.1 hereto) | |||||||||||
23.4* | Consent of ThinkEquity | |||||||||||
24.1* | Power of Attorney (included on the signature page) | |||||||||||
99.1* | Opinion of ThinkEquity, financial advisor to MYnd Analytics, Inc. (included as Annex C to the joint proxy statement/prospectus forming a part of this Registration Statement) | |||||||||||
99.2* | Form of MYnd Analytics, Inc. Proxy Card | |||||||||||
99.3* | Form of Emmaus Life Sciences, Inc. Proxy Card | |||||||||||
99.4* | Proposed Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MYnd Analytics, Inc. for Reverse Stock Split (included as Annex D to the joint proxy statement/prospectus forming a part of this Registration Statement) | |||||||||||
99.5* | Proposed Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MYnd Analytics, Inc. for Name Change (included as Annex E to the joint proxy statement/prospectus forming a part of this Registration Statement) | |||||||||||
99.6* | Consent of Yutaka Niihara, M.D., M.P.H. to be named as a director | |||||||||||
99.7* | Consent of Willis C. Lee, M.S. to be named as a director | |||||||||||
99.8* | Consent of Robert Dickey IV to be named as a director | |||||||||||
99.9* | Consent of Masaharu Osato, M.D. to be named as a director | |||||||||||
99.10* | Consent of Wei Peu Zen to be named as a director | |||||||||||
99.11* | Consent of Ian Zwicker to be named as a director |
* | Previously Filed |
** | Filed herewith |
† | Management compensatory plan, contract or arrangement |
+ | All schedules (or similar attachments) have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. MYnd Analytics, Inc. will furnish copies of any schedules to the Securities and Exchange Commission upon request. |
II-5
Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Mission Viejo, State of California, on the 11th day of June, 2019.
MYND ANALYTICS, INC. | ||
By: | /s/ Patrick Herguth | |
Name: | Patrick Herguth | |
Title: | Chief Executive Officer |
Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
Signature | Signature | Date | ||
/s/ Patrick Herguth | Chief Executive Officer and Director | June 11, 2019 | ||
Patrick Herguth | (Principal Executive Officer) | |||
* | Chief Financial Officer | June 11, 2019 | ||
Donald E. D’Ambrosio | (Principal Financial and Accounting Officer) | |||
* | ||||
Robin L. Smith, M.D. | Chairman of the board of directors | June 11, 2019 | ||
* | ||||
Geoffrey E. Harris | Director | June 11, 2019 | ||
* | ||||
John Pappajohn | Director | June 11, 2019 | ||
* | ||||
Peter Unanue | Director | June 11, 2019 | ||
* | ||||
Michal Votruba | Director | June 11, 2019 |
*By: | /s/ Patrick Herguth | |
Patrick Herguth | ||
Attorney-in-Fact |
II-6